Modeling results / SDF: Routine vaccination strategy Introduction catch-up strategy
|
|
- Samson Cobb
- 5 years ago
- Views:
Transcription
1 Modeling results / SDF: Routine vaccination strategy Introduction catch-up strategy Ira Longini, Diana Rojas, Tom Hladish CSQUID, University of Florida, Gainesville, FL Betz Halloran, Dennis Chao Fred Hutchinson Research Center, University of Washington, Seattle, WA Hector Gomez Dantes National Institute of Public Health, Cuernavaca, México First Regional Dengue Symposium Río de Janeiro, Brasil, Noviembre 3-4, 2015
2 This talk Concepts in vaccine efficacy and effectiveness Dengue vaccines under development Description of individual-level, stochastic simulation model Potential effectiveness and impact of dengue vaccine Catchup Waning Combining dengue vaccines with vector control
3 Current dengue intervention use and impact modeling Vaccine effectiveness depends on Vaccine efficacy Durability of protection Force of infection of each serotype Mix of serotypes circulating Level of immunity in the population Age structure of the population Change immunity patterns Level of exposure
4 Current dengue intervention use and impact modeling Vector control effectiveness Need for integrated vector control for established methods Need to establish the relationship between vector control methods and dengue illness and infection More field studies Biological control Genetic Biological, e.g., Wolbachia, copepods
5 5
6 Overall effectiveness and impact Overall effectiveness VE overall = 1 (r vac /r novac ) r vac overall incidence rate with vaccination campaign r novac overall incidence rate with no vaccination in a comparable population VPDI overall = (#risk) r novac VE overall, cases averted = (#risk) (r novac r vac )
7 Sanofi dengue vaccine so far Very safe Reasonable protection for disease with infection so far Longer term follow-up needed for durability of immunity and protection Excellent protect against severe disease Heterogeneity in protection Serotypes Prior immunity Other factors?
8 Individual-level, stochastic, mathematical model Chao DL, Halstead SB, Halloran ME, Longini IM: Controlling dengue with vaccines in Thailand, PLoS Negl Top Dis (2012). Chao DL, Halloran ME, Longini IM: The effects of vector movement and distribution in a dengue transmission model. PLoS One (2013) Hladish T, Pulliam J, Longini IM, Gomez HD, et al.: Projected impact of dengue vaccination in Mexico (2015).
9 Model: Natural history of dengue Human SEIR is linked to mosquito SEI model Humans and mosquitoes infect each other when they are in the same setting
10 Model Structure: dengue model Yucatán State overview (Agent-based model) People stay home, or go to work or school each day Mosquitoes stay put or occasionally move to adjacent location each day Uninfected mosquitoes are modeled probabilistically, infected mosquitoes modeled explicitly Model based on Chao et al (2012), PLOS NTD
11 Dengue eras modelled in Yucatan Pre-history (before 1956) Elimination ( ) Fitting ( ) Forecast ( )
12 Serotype Reported cases Dengue in Yucatan,
13 Pixel size = 430m x 460m Households are placed within municipalities according to nighttime light output (VIIRS/NASA)
14 Households
15 Workplaces & schools
16 Mosquito movement Mosquitoes move according to Delaunay triangulation
17
18 Observed seasonality ( )
19 Pr{Rainfall} Mosquito population
20 Temperature Incubation Period, after Chan and Johanson (2012)
21 Seasonality Fit to data using Approximate Bayesian Computation (ABC) Timing of peak matches Width of peak may be narrow because model s seasonality doesn t change
22 Duration of cross immunity = 2 years
23 Immune profile validation 95% CI bars on empirical data
24 Yucatan Simulation
25 Vaccine efficacy for simulations Latin America Serotype Vaccine Efficacy * Antibody positive Antibody negative Overall ** * Assuming leaky vaccine effect ** Based on 60% antibody positive
26 Vaccination strategies Routine vaccination Vaccination of 2, 9 or 16 year-olds every year Routine vaccination with one-time catchup Vaccination of 2, 9 or 16 year-olds every year One time catch-up up to 30 Coverage: 80% coverage for 9 year-old routine 60% coverage for year-old catchup Same # doses for others
27 Yucatan Simulation with Vaccination
28
29
30 Cumulative severe cases (DHF/DSS) averted per 100,000 at risk Years 1-5 Years 1-10 Years 1-15 Years yo routine yo catch-up
31 Conclusions Routine vaccination of children Overall effectiveness starts near 0% and goes to 50% Prevent 1,000 severe cases/100,000 over 20 years Routine vaccination of children + one time catch up to 30 Overall effectiveness starts near 50% and goes to 75% Prevent 2,100 severe cases/100,000 over 20 years
32 Potential effects of vaccine efficacy waning
33 Waning Patterns
34
35
36 Conclusions about waning Even longer-term waning would be problematic Could make the epidemic worse Boosting strategies would be necessary Depending on waning speed, boosting should take place at appropriate intervals Vaccination with boosting strategies could be worked out using mathematical models
37 Vector reduction model Simulate past dynamics ( ) Reduce mosquito population by 10, 25, or 50% ( ) Vector reduction vector control
38
39
40 Why does vector reduction lose effectiveness? Initially: High natural immunity + VC = small epidemics Later: Modest natural immunity + VC = ~normal epidemics What if we stop?
41
42 Vector-only conclusions Noise may obscure empirical effectiveness Vector-reduction only is ambitious/problematic Stop slowly
43 Effects of new vector reduction plus vaccination
44
45 Vector reduction + routine vaccination 10% VR 25% VR 50% VR Stable effectiveness possible
46 Vector reduction + routine + catchup vaccination 10% VR 25% VR 50% VR
47 Overall conclusions Modest interventions not bad, may be untenable Vector reduction effectiveness wanes Routine vaccination effectiveness starts low Combined modest interventions promising Increased, sustained effectiveness Ambitious VR and catchup not needed Cost-benefit analysis needed to find balance
48 Funding Sources Dengue Vaccine Initiative/Bill and Melinda Gates Foundation NIH, NIAID R37 AI32042 NIH, NIGMS U54 GM (MIDAS) Sanofi Pasteur (Phase IV studies in the Yucatan)
49 Gracias
50 Measures of Vaccine Efficacy VE S Vaccine Effect on Susceptibility VE P Vaccine Effect on Clinical Disease Classical III vaccine trials Many times observe VE SP = 1 (1 VE S ) (1 VE P ) VE I Vaccine Effect on Infectiousness Search for immune correlates (even surrogates for VE)
51 Summary: CYD 15 * Overall VE SP = 60.8% [CI: ] ** Overall VE Hosp = 80.3% [CI: ] Serotype-specific VE SP ST1: 50.3% [CI: ] ST2: 42.3% [CI: ] ST3: 74.0% [CI: ] ST4: 77.7% [CI: ] Vaccine more efficacious in people with prior immunity compared to those who are naïve, 2 to 1 ratio, accounts for age differences in VE *Villar, et al., N Engl J Med. (2014), ** Per-protocol analysis
52 Phase IIb and III vaccine trials of Sanofi Pasteur tetravalent dengue vaccine Phase I and II in many countries Phase IIb completed in Thailand (CYD23) * Phase III completed late countries in SE Asia (CYD14) ** 5 countries in Latin America (CYD15) *** * Sabchareon, et al. Lancet (2012) ** Capeding, et al., Lancet (2014) *** Villar, et al., N Engl J Med (2014)
53 Stepped wedge cluster trial One-way cross-over cluster trial Randomized, phased introduction on a facility by facility basis until all facilities have received intervention Time points informed by Type of disease, outcome, time to expected effect etc. Higher risk of bias compared to randomized control trials (RCT) Less efficient than RCT but more efficient than cluster trial Source: Matthias Egger Typically requires more time
Lecture 9: Stochastic models for arboviruses. Ira Longini
Lecture 9: Stochastic models for arboviruses Ira Longini The Ross-MacDonald Model for Vector Bourne Infectious Diseases Sir Ronald Ross (1857-1932) Liverpool School of Tropical Medicine The 2 nd Nobel
More informationMathematical Models for the Control of Infectious Diseases With Vaccines
Mathematical Models for the Control of Infectious Diseases With Vaccines Ira Longini Department of Biostatistics and Center for Statistical and Quantitative Infectious Diseases (CSQUID), University of
More informationAssessment of dengue vaccine effectiveness and impact for different rollout strategies
Assessment of dengue vaccine effectiveness and impact for different rollout strategies Diana P. Rojas and Ira Longini Center for Inference and Dynamics of Infectious Diseases Emerging Pathogens Institute
More informationLecture 4: Stochastic models for arboviruses. Ira Longini
Lecture 4: Stochastic models for arboviruses Ira Longini The Ross-MacDonald Model for Vector Bourne Infectious Diseases Sir Ronald Ross (1857-1932) Liverpool School of Tropical Medicine The 2 nd Nobel
More informationModeling the effectiveness of mass cholera vaccination in Bangladesh
Modeling the effectiveness of mass cholera vaccination in Bangladesh Dennis Chao April 20, 2016 1 / 20 Vibrio cholerae in Bangladesh Ali et al. Updated Global Burden of Cholera in Endemic Countries. PLoS
More informationEdwin J. Asturias Associate Director
Edwin J. Asturias Associate Director Center for Global Health Associate Professor of Pediatrics and Epidemiology Effectiveness Dengue Vaccine Washington DC, June 2014 UNIVERSITY OF COLORADO COLORADO STATE
More informationThe design and analysis of Phase IIb Ebola vaccine trials
The design and analysis of Phase IIb Ebola vaccine trials Ira Longini Department of Biostatistics Center for Statistical and Quantitative Infectious Diseases (CSQUID) Emerging Pathogens Institute University
More informationMathematical modeling of cholera
Mathematical modeling of cholera Dennis Chao Center for Statistics and Quantitative Infectious Diseases (CSQUID) Vaccine and Infectious Disease Division Fred Hutchinson Cancer Research Center 22 April,
More informationProjections of Zika spread in the Continental US
Projections of Zika spread in the Continental US Qian Zhang 1, Kaiyuan Sun 1, Matteo Chinazzi 1, Ana Pastore-Piontti 1, Natalie E. Dean 2, Diana Patricia Rojas 3, Stefano Merler 4, Dina Mistry 1, Piero
More informationThe Transmissibility and Control of Pandemic Influenza A (H1N1) Virus
The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus Yang Yang, 1 Jonathan D. Sugimoto, 1,2 M. Elizabeth Halloran, 1,3 Nicole E. Basta, 1,2 Dennis L. Chao, 1 Laura Matrajt, 4 Gail Potter,
More informationSAGE deliberations on CYD-TDV ( Dengvaxia )
SAGE deliberations on CYD-TDV ( Dengvaxia ) Annelies Wilder-Smith Consultant, Vaccines for Arboviral Diseases, WHO-IVB Scientific Coordinator ZIkaPLAN Director, Partnership for Dengue Control, Fondation
More informationDependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine
Dependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine Yang Yang, PhD 1, Ya Meng, PhD 1, M. Elizabeth Halloran, DSc, MD 2,3, Ira M. Longini, Jr., PhD 1 August
More informationResults of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine
Results of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine Maria Rosario Z. Capeding, MD Research Institute for Tropical Medicine Philippines From
More informationDengue Vaccine (CYD-TDV Dengvaxia )
Dengue Vaccine (CYD-TDV Dengvaxia ) Annelies Wilder-Smith Consultant, Vaccines for Arboviral Diseases, WHO-IVB Lee Kong Chian School of Medicine, Singapore Director, Partnership for Dengue Control, Fondation
More informationImmune protection against dengue infection. Vaccine performance
Immune protection against dengue infection. Vaccine performance SCOTT B HALSTEAD MD Department of Preventive Medicine Uniformed Services University of the Health Sciences TOPICS Current dengue vaccines:
More informationCYD-TDV Dengvaxia clinical update
Chris Nelson Sanofi Pasteur CYD-TDV Dengvaxia clinical update "Arboviruses: A Global Public Health Threat" 20-22 June 2018 Les Pensières Center for Global Health, Veyrier-du-Lac (France) JUNE 2018 1 The
More informationTowards Dengue Vaccine Introduction:! Report of the Asia-Pacific Dengue Prevention Board Meeting
Towards Dengue Vaccine Introduction:! Report of the Asia-Pacific Dengue Prevention Board Meeting Sri Rezeki S Hadinegoro Department of Child Health Medical Faculty University of Indonesia Lay out Introduction
More informationAnalytic Methods for Infectious Disease Lecture 3
Analytic Methods for Infectious Disease Lecture 3 M. Elizabeth Halloran Hutchinson Research Center and University of Washington Seattle, WA, USA January 13, 2009 Herd Immunity Definition Manifestations
More informationGenerating potential demand and impact estimates to inform dengue vaccine introduction in Brazil and Mexico
International Vaccine Access Center at Johns Hopkins Generating potential demand and impact estimates to inform dengue vaccine introduction in Brazil and Mexico Asia Dengue Summit 13-14 January, 2016 Bangkok,
More informationDengue Vaccines: Herd Immunity Considerations
1/33 Dengue Vaccines: Herd Immunity Considerations Derek Cummings Johns Hopkins Bloomberg School of Public Health Fondation Merieux, October 27, 2010 2/33 Outline 1 2 3 Immune enhancement of transmission
More informationLEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS
FACT SHEET LEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS A GLOBAL PUBLIC HEALTH CHALLENGE Dengue fever, a mosquito-borne disease caused by four types of dengue viruses, is a threat
More informationFlavivirus Vaccines Japanese Encephalitis and Dengue
Flavivirus Vaccines Japanese Encephalitis and Dengue 14 th Advanced Vaccinology Course Veyrier du Lac, France May 16, 2012 Harold S. Margolis, MD Dengue Branch Centers for Disease Control and Prevention
More informationDengue Vaccines: Status and Future
Dengue Vaccines: Status and Future In-Kyu Yoon, M.D. International Vaccine Institute Director, Global Dengue & Aedes-Transmitted Diseases Consortium 22 Jun 2018 Outline Tetravalent vaccination strategy
More informationModule 5: Introduction to Stochastic Epidemic Models with Inference
Module 5: Introduction to Stochastic Epidemic Models with Inference Instructors: Tom Britton, Dept. Mathematics, Stockholm University Ira Longini, Dept. Biostatistics, University of Florida Jonathan Sugimoto,
More informationDengue vaccine โดย ศ. พญ. ก ลก ญญา โชคไพบ ลย ก จ ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร ศ ร ราชพยาบาล
Dengue vaccine โดย ศ. พญ. ก ลก ญญา โชคไพบ ลย ก จ ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร ศ ร ราชพยาบาล SANOFI PASTEUR S DENGUE VACCINE*: THE MOST CLINICALLY ADVANCED DENGUE VACCINE CANDIDATE There are 4 genetic
More informationThe Effects of Vector Movement and Distribution in a Mathematical Model of Dengue Transmission
The Effects of Vector Movement and Distribution in a Mathematical Model of Dengue Transmission Dennis L. Chao 1 *, Ira M. Longini Jr. 2, M. Elizabeth Halloran 1,3 1 Center for Statistics and Quantitative
More informationVaccines on the Global Scale
Vaccines on the Global Scale Learning from the past and aiming at the future Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health,
More informationDengue: The next vaccine preventable disease? Prof John McBride James Cook University
Dengue: The next vaccine preventable disease? Prof John McBride James Cook University Dengue viruses A flavivirus ~11kb genome, ~50nm diameter, lipid envelope. Gene order 5 C-prM-E-NS1 Four serotypes (1-4)
More informationUpdated Questions and Answers related to the dengue vaccine Dengvaxia and its use
WHO Secretariat Updated Questions and Answers related to the dengue vaccine Dengvaxia and its use Published 22 December 2017 This document takes into account new and unpublished data that were communicated
More informationEvaluating the Impact of a Tetravalent Vaccine in Populations with High-Incidence of Dengue: A Mathematical Model
Nonlinear Analysis and Differential Equations, Vol. 4, 216, no. 3, 133-142 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/1.12988/nade.216.51148 Evaluating the Impact of a Tetravalent Vaccine in Populations
More informationSummary of Key Points WHO Position Paper on Dengue Vaccine, September 2018
Summary of Key Points WHO Position Paper on Dengue Vaccine, September 2018 For more information on the WHO Dengue position paper, please visit the WHO website: www.who.int/immunization/documents/positionpapers
More informationDengue Experience and Implications for Vaccine Development
Dengue Experience and Implications for Vaccine Development In-Kyu Yoon, M.D. International Vaccine Institute Director, Global Dengue & Aedes-Transmitted Diseases Consortium 28 Jun 2018 Mission: To promote
More informationRegulatory Considerations for Determining Vaccine Efficacy U.S. FDA Perspective
Regulatory Considerations for Determining Vaccine Efficacy U.S. FDA Perspective Marion Gruber, PhD. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research Food and Drug
More informationModule 5: Introduction to Stochastic Epidemic Models with Inference
Module 5: Introduction to Stochastic Epidemic Models with Inference Instructors:, Dept. Mathematics, Stockholm University Ira Longini, Dept. Biostatistics, University of Florida Jonathan Sugimoto, Vaccine
More informationMODULE 5. Dengue. Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America
MODULE 5 Dengue Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America Symptoms of Dengue Fever Dengue: Skin rashes DHF manifestations Hemorrhages Thrombocytopenia
More informationEPIDEMIOLOGY AND TRANSMISSION DYNAMICS OF ARBOVIRUS IN LATIN AMERICA
EPIDEMIOLOGY AND TRANSMISSION DYNAMICS OF ARBOVIRUS IN LATIN AMERICA By DIANA P. ROJAS ALVAREZ A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE
More informationNew epidemiological perspectives coming from dengue vaccine clinical trials. João Bosco Siqueira Jr Federal University of Goias - Brazil
New epidemiological perspectives coming from dengue vaccine clinical trials João Bosco Siqueira Jr Federal University of Goias - Brazil Dengue Key Facts The global incidence of dengue has grown dramatically
More informationsp second generation tetravalent dengue vaccine
sp second generation tetravalent dengue vaccine CYD23 Study Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 1 Years in Thailand Alain Bouckenooghe, MD, MPH, DTM&H Clinical R&D, Head
More informationGlobal Dengue Vaccine Recommendations and Considerations for Vaccine Decision-Making. Asia Dengue Summit, Bangkok January 2016
Global Dengue Vaccine Recommendations and Considerations for Vaccine Decision-Making Asia Dengue Summit, Bangkok 13-14 January 2016 Joachim Hombach Initiative for Vaccine Research (IVR) Department of Immunization,
More informationASSESSING THE VALUE OF VACCINE BEYOND EFFICACY AND SAFETY
ASSESSING THE VALUE OF VACCINE BEYOND EFFICACY AND SAFETY Bradford D. Gessner, MD Agence de Médecine Preventive First Regional Dengue Symposium Rio de Janeiro, Brasil November 3-4, 2015 BURDEN CONCEPTS
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationDengue Conference, Mandurai, India, July What role should mathematical models & transgenic mosquitoes play in dengue control programs in India?
Dengue Conference, Mandurai, India, July 2013 What role should mathematical models & transgenic mosquitoes play in dengue control programs in India? John M. Marshall Department of Infectious Disease Epidemiology,
More informationMathematical modelling of infectious disease transmission
Mathematical modelling of infectious disease transmission Dennis Chao Vaccine and Infectious Disease Division Fred Hutchinson Cancer Research Center 11 May 2015 1 / 41 Role of models in epidemiology Mathematical
More informationAuchara Tangsathapornpong 1, Churairat Puriburt 2 and Pornumpa Bunjoungmanee 1
EPIDEMIOLOGY OF DENGUE AT THAMMASAT UNIVERSITY HOSPITAL DURING 2006-2015 Auchara Tangsathapornpong 1, Churairat Puriburt 2 and Pornumpa Bunjoungmanee 1 1 Department of Pediatrics, Faculty of Medicine,
More informationMATHEMATICAL MODEL OF LYME DISEASE CAUSED BY THE BACTERIUM BORRELIA BURGDORFERRI
Wednesday, 25th, 10:30 MATHEMATICAL MODEL OF LYME DISEASE CAUSED BY THE BACTERIUM BORRELIA BURGDORFERRI Antoni Leon Dawidowicz Antoni.Leon.Dawidowicz@im.uj.edu.pl Faculty of Mathematics and Computer Science,
More informationAUGMENTED HIV VACCINE TRIAL DESIGN FOR ESTIMATING REDUCTION IN INFECTIOUSNESS AND PROTECTIVE EFFICACY
STATISTICS IN MEDICINE, VOL. 17, 185 200 (1998) AUGMENTED HIV VACCINE TRIAL DESIGN FOR ESTIMATING REDUCTION IN INFECTIOUSNESS AND PROTECTIVE EFFICAC SUSMITA DATTA, M. ELIZABETH HALLORAN* AND IRA M. LONGINI,
More informationOverview of a neglected infectious disease: dengue
Overview of a neglected infectious disease: dengue Outline Current epidemiological trends Mechanisms underlying dengue transmission Dengue control Overview of recent modeling efforts Drivers of serotype
More informationBIOST/STAT 578 A Statistical Methods in Infectious Diseases Lecture 16 February 26, Cholera: ecological determinants and vaccination
BIOST/STAT 578 A Statistical Methods in Infectious Diseases Lecture 16 February 26, 2009 Cholera: ecological determinants and vaccination Latest big epidemic in Zimbabwe Support International Vaccine
More informationData inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov
Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov Vaccine & Infectious Disease Division Fred Hutchinson Cancer Research Center Dynamic model integration The
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationThe Effectiveness of Dengue Vaccine and Vector Control: Model Study
KMUTNB Int J Appl Sci Technol, Vol. 11, No. 3, pp. 225 232, 218 Research Article The Effectiveness of Dengue Vaccine and Vector Control: Model Study Sittisede Polwiang* Department of Mathematics, Faculty
More informationMarc Baguelin 1,2. 1 Public Health England 2 London School of Hygiene & Tropical Medicine
The cost-effectiveness of extending the seasonal influenza immunisation programme to school-aged children: the exemplar of the decision in the United Kingdom Marc Baguelin 1,2 1 Public Health England 2
More informationVaccine prevention for existing and emerging viral threats
Vaccine prevention for existing and emerging viral threats Viruses in May Blue Mountains 18 May 2018 www.ncirs.edu.au https://www.apprise.org.au/ Prof Kristine Macartney Director, NCIRS www.ncirs.usyd.edu.au
More informationBACKGROUND PAPER ON DENGUE VACCINES
BACKGROUND PAPER ON DENGUE VACCINES REVISION TO THE BACKGROUND PAPER FROM 17 MARCH 2016 PREPARED BY THE SAGE WORKING GROUP ON DENGUE VACCINES AND WHO SECRETARIAT 18 APRIL 2018 1 TABLE OF CONTENTS 1. Executive
More informationLecture 9: Study designs for evaluating vaccine efficacy N ATA L IE DEA N A N D IRA LON GIN I
Lecture 9: Study designs for evaluating vaccine efficacy N ATA L IE DEA N A N D IRA LON GIN I DEPARTMENT OF BIOSTATISTICS UN IV ERSITY OF FLORIDA Goal of vaccine studies Evaluate vaccine efficacy and effectiveness
More informationSimulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
Epidemiol. Infect. (214), 142, 124 128. Cambridge University Press 213 doi:1.117/s92688131866 Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control U. THAVARA 1,A.TAWATSIN
More informationPredicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus
JOURNAL OF VIROLOGY, Oct. 2004, p. 11340 11351 Vol. 78, No. 20 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.20.11340 11351.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Predicting
More informationA Global Overview of the Chikungunya Virus Problem
A Global Overview of the Chikungunya Virus Problem Ann M. Powers, Ph.D. Division of Vector-Borne Infectious Diseases Centers for Disease Control and Prevention Chikungunya Virus Family Togaviridae,, genus
More informationEben Kenah 380F Cunz Hall 1841 Neil Avenue Columbus, OH
Associate Professor Divisions of Biostatistics and Epidemiology College of Public Health The Ohio State University Eben Kenah 380F Cunz Hall 1841 Neil Avenue Columbus, OH 43210 kenah.1@osu.edu Education
More informationEben Kenah 22 Buckman Drive, Dauer Hall 464 P. O. Box Gainesville, FL
Assistant Professor Department of Biostatistics University of Florida Eben Kenah 22 Buckman Drive, Dauer Hall 464 P. O. Box 117450 Gainesville, FL 32611 352-294-1935 ekenah@ufl.edu Education 03/2008 ScD,
More informationPrevention of arboviral diseases. Willem Takken & Sander Koenraadt Laboratory of Entomology Wageningen University and Research
Prevention of arboviral diseases Willem Takken & Sander Koenraadt Laboratory of Entomology Wageningen University and Research Brussel, 25 januari 2018 Arbivoral diseases affecting humans Mosquito borne:
More informationMathematical Modelling the Spread of Zika and Microcephaly in Brazil.
Proceedings of the 17th International Conference on Computational and Mathematical Methods in Science and Engineering, CMMSE 2017 4 8 July, 2017. Mathematical Modelling the Spread of Zika and Microcephaly
More informationWould a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children?
Would a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children? Philippe De Wals Department of Social and Preventive Medicine, Laval University Quebec University Hospital
More informationWhat do epidemiologists expect with containment, mitigation, business-as-usual strategies for swine-origin human influenza A?
What do epidemiologists expect with containment, mitigation, business-as-usual strategies for swine-origin human influenza A? Dr Thomas TSANG Controller, Centre for Health Protection, Department of Health
More informationThe Effects of Herd Immunity on the Power of Vaccine Trials
University of California, Los Angeles From the SelectedWorks of Ron Brookmeyer 2009 The Effects of Herd Immunity on the Power of Vaccine Trials Blake Charvat Ron Brookmeyer, Johns Hopkins Bloomberg School
More informationMathematics 4MB3/6MB3 Mathematical Biology
Mathematics and Statistics dω = ω M M Mathematics 4MB3/6MB3 Mathematical Biology Instructor: Guillaume Blanchet Lecture 22 Synchrony - Part 6 March 4 th 2015 Application of simple coherence criteria 10
More informationDENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo
DENGUE AND BLOOD SAFETY Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo Dengue virus Arbovirus (arthropod-borne virus) virus transmitted by mosquitoes:
More informationStrategies for containing an emerging influenza pandemic in South East Asia 1
Strategies for containing an emerging influenza pandemic in South East Asia 1 Modeling pandemic spread and possible control plans of avian flu H5N1 BBSI, Nicole Kennerly, Shlomo Ta asan 1 Nature. 2005
More informationInfluenza Vaccines in older persons 65+ Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition
Influenza Vaccines in older persons 65+ Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition Outline 1. Influenza in older persons 2. Vaccine effectiveness in the elderly including
More informationDengue is one of the most rapidly spreading mosquito-borne viral diseases in the world and
Abstract Dengue is one of the most rapidly spreading mosquito-borne viral diseases in the world and inflicts significant health, economic and social burden on populations. Various mathematical models have
More informationJonathan D. Sugimoto, PhD Lecture Website:
Jonathan D. Sugimoto, PhD jons@fredhutch.org Lecture Website: http://www.cidid.org/transtat/ 1 Introduction to TranStat Lecture 6: Outline Case study: Pandemic influenza A(H1N1) 2009 outbreak in Western
More informationJune 15 - July 1, 2009
1ST SUMMER INSTITUTE IN STATISTICS AND MODELING IN INFECTIOUS DISEASES June 15 - July 1, 2009 UNIVERSITY of WASHINGTON Seattle, Washington http://depts.washington.edu/sismid09 SISMID 2009 Sponsored by:
More informationConcepts of herd protection and immunity
Available online at www.sciencedirect.com Procedia in Vaccinology 2 (2010) 134 139 Ninth Global Vaccine Research Forum and Parallel Satellite Symposia, Bamako, Mali, 6-9 December 2009 Concepts of herd
More informationAdvances in epidemic forecasting & implications for vaccination
Centers for Disease Control and Prevention Advances in epidemic forecasting & implications for vaccination Michael A. Johansson Epidemic Prediction Initiative Division of Vector-Borne Diseases, San Juan,
More informationComputational Epidemiology
Computational Epidemiology as a tool for Understanding the Complex Interactions that Confront Public Health Decision Making Bryan Lewis MPH Network Dynamics and Simulation Science Laboratory Preview Pubic
More informationDengue Vaccines: current status of development
Dengue Vaccines: current status of development ISID-NTD 2011 International Meeting, Boston Satellite Symposium on Dengue Control, 10 July 2011 Pem Namgyal WHO/IVB/IVR 1 Presentation Outline! Summary of
More informationWhen infections go viral Zika Virus
When infections go viral Zika Virus John Fangman, MD Associate Professor of Medicine (Infectious Diseases) Senior Medical Director of Ambulatory, Medical College Physicians Medical College of Wisconsin
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationMY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS
MY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS MARCH 3, 2017 LAUREN M. SCHWARTZ, MSPH PHD CANDIDATE LAURENMS@UW.EDU OUTLINE FOR TODAY What do you want to get out
More informationEvidence review on the immunogenicity, efficacy/effectiveness and safety of typhoid conjugate vaccines
Evidence review on the immunogenicity, efficacy/effectiveness and safety of typhoid conjugate vaccines SAGE meeting, Geneva, 17-19 October, 2017 Myron M. (Mike) Levine, MD, DTPH Grollman Distinguished
More informationArbovirus Essentials: Biology, Transmission, and Clinical Features
OUR MISSION Founded in 1991, the Colorado Children s Immunization Coalition (CCIC) is a statewide 501(c)3 nonprofit that strategically mobilizes diverse partners and families to advance children s health
More informationThe importance of schools and other non-household sites for dengue entomological risk
The importance of schools and other non-household sites for dengue entomological risk Audrey Lenhart, MPH, PhD US Centers for Disease Control and Prevention (CDC) Liverpool School of Tropical Medicine
More informationModelling the risk of dengue for tourists in Rio de Janeiro, during. Janeiro, during the FIFA confederation cup in Brazil 2013
Modelling the risk of dengue for tourists in Rio de Janeiro, during the FIFA confederation cup in Brazil 2013 Raphael Ximenes, Eduardo Massad University of São Paulo November, 2013 Mathematical modeling
More informationProceedings of the 2014 Winter Simulation Conference A. Tolk, S. Y. Diallo, I. O. Ryzhov, L. Yilmaz, S. Buckley, and J. A. Miller, eds.
Proceedings of the 2014 Winter Simulation Conference A. Tolk, S. Y. Diallo, I. O. Ryzhov, L. Yilmaz, S. Buckley, and J. A. Miller, eds. OPTIMAL DISTRIBUTION OF THE INFLUENZA VACCINE Osman Y. Özaltın Department
More informationThe DENGUE Vaccine. Salvacion Rodriguez Gatchalian, MD, FPPS, FPISP, FPSMID Associate Professor, UP College of Medicine
The DENGUE Vaccine Salvacion Rodriguez Gatchalian, MD, FPPS, FPISP, FPSMID Associate Professor, UP College of Medicine GLOBAL DENGUE FACTS 2.5 billion people, or 40% of the world s population, live in
More informationWhat do we know (or don t know) about Zika incidence and geographic spread that is critical for planning vaccine trials?
What do we know (or don t know) about Zika incidence and geographic spread that is critical for planning vaccine trials? Laura C Rodrigues, Prof Infectious Disease Epidemiology, LSHTM and Microcephaly
More informationTraining in Infectious Diseases Modeling. A reflection on vaccination as a disease control measure
Training in Infectious Diseases Modeling A reflection on vaccination as a disease control measure -Example of Rotavirus disease- Participant s Guide Adapted by Nathalie Elomeiri; Camelia Savulescu; Fernando
More informationCreating VaCCines, ProteCting Life
Creating VaCCines, ProteCting Life PreVenting Disease through VaCCination a Constant BattLe Immunization has been a great public health success story. The lives of millions of children have been saved,
More informationLessons of Disease Eradication Efforts for Invasive Mussel Control. Jim Koopman MD MPH, Professor Emeritus
Lessons of Disease Eradication Efforts for Invasive Mussel Control Jim Koopman MD MPH, Professor Emeritus Talk Organization Antecedents to Smallpox Eradication philosophy Yellow fever and Malaria Smallpox,
More informationTuberculosis Tutorials
Tuberculosis Tutorials These tuberculosis (TB) tutorials were created for the EMOD QuickStart v1.8. Later versions of the QuickStart may not be completely compatible with these tutorials as installation
More informationHarvard University. Leveraging Contact Network Structure in the Design of Cluster Randomized Trials
Harvard University Harvard University Biostatistics Working Paper Series Year 2016 Paper 199 Leveraging Contact Network Structure in the Design of Cluster Randomized Trials Guy Harling Rui Wang Jukka-Pekka
More informationPre-clinical Development of a Dengue Vaccine. Jeremy Brett Sanofi Pasteur, Singapore
Pre-clinical Development of a Dengue Vaccine Jeremy Brett Sanofi Pasteur, Singapore Dengue Vaccine B Guy 1 Talk flow Introduction: What are the challenges of dengue vaccine development? The Virus The host
More informationEnsemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic Malaria Vaccine
Ensemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic Malaria Vaccine Thomas Smith 1,2 *, Amanda Ross 1,2, Nicolas Maire 1,2, Nakul Chitnis 1,2, Alain Studer 1,2, Diggory Hardy 1,2,
More informationModelling global epidemics: theory and simulations
Modelling global epidemics: theory and simulations Marc Barthélemy CEA, IPhT, France marc.barthelemy@cea.fr Manchester meeting Modelling complex systems (21-23 june 2010) Outline Introduction Metapopulation
More informationMY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS
MY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS MARCH 2, 2018 LAUREN M. SCHWARTZ, MSPH PHD CANDIDATE LAURENMS@UW.EDU OUTLINE FOR TODAY What do you want out of your
More informationSanofi updates information on dengue vaccine. 29 November 2017 (Sanofi Press Release)
Sanofi updates information on dengue vaccine 29 November 2017 (Sanofi Press Release) Based on up to six years of clinical data, a new analysis evaluated long-term safety and efficacy of Dengvaxia in people
More informationProposal for a Workshop
Proposal for a Workshop Pre-vaccination screening for the use of dengue vaccines with differential performance dependent on serostatus: rapid diagnostic tests and implementation strategies Background:
More informationFIRST MEETING OF THE TECHNICAL ADVISORY GROUP ON PUBLIC HEALTH ENTOMOLOGY PAN AMERICAN HEALTH ORGANIZATION
SUMMARY FIRST MEETING OF THE TECHNICAL ADVISORY GROUP ON PUBLIC HEALTH ENTOMOLOGY PAN AMERICAN HEALTH ORGANIZATION The first meeting of the Technical Advisory Group on Public Health Entomology (TAG PHE),
More informationImpact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials
Clinical Infectious Diseases MAJOR ARTICLE Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials Eric Plennevaux, 1 Annick Moureau, 2 José L. Arredondo-García,
More informationUNICEF ZIKA Diagnostics VACCINES Demand Forecast. Jorgen Kofoed UNICEF SD
UNICEF ZIKA Diagnostics VACCINES Demand Forecast Jorgen Kofoed UNICEF SD 1 Forecasting model: Overview Assesses various methodologies and targeting assumptions Applies 10-year time horizon incorporating
More information